DCW234
DCW234, also known as butyl 4-(butyryloxy)benzoate, is a synthetic nonsteroidal estrogen and a selective agonist of the ERβ.[1][2][3] It shows modest selectivity in terms of affinity and transactivation for the ERβ over the ERα.[1] Its affinity for the ERβ was 3.43 μM and for the ERα was 22.5 μM, while it activated the ERβ and ERα with EC50 values of 1.71–2.5 μM and 19.8–22.5 μM, respectively.[1] As such, its binding selectivity for the ERβ over the ERα was 7-fold and its functional selectivity for the ERβ over the ERα was between 10- and 13-fold.[1]
 | |
| Clinical data | |
|---|---|
| Other names | Butyl 4-(butyryloxy)benzoate |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C15H20O4 |
| Molar mass | 264.321 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
References
- Lin Z, Shen H, Huang J, Chen S, Chen L, Chen J, Liu G, Jiang H, Shen X (2008). "Butyl 4-(butyryloxy)benzoate functions as a new selective estrogen receptor beta agonist and induces GLUT4 expression in CHO-K1 cells". J. Steroid Biochem. Mol. Biol. 110 (1–2): 150–6. doi:10.1016/j.jsbmb.2008.03.028. PMID 18455388.
- Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA (2011). "Estrogen receptor β ligands: recent advances and biomedical applications". Med Res Rev. 31 (3): 364–442. doi:10.1002/med.20186. PMID 19967775.
- Serock MR, Wells AK, Khalil RA (2008). "Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause". Recent Pat Cardiovasc Drug Discov. 3 (3): 165–86. doi:10.2174/157489008786263970. PMID 18991792.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.